LOINCActive

LOINC Code 62965-9: PhenX - health impact of inflammatory bowel disease protocol 190701

62965-9 is a LOINC code used to identify PhenX - health impact of inflammatory bowel disease protocol 190701 in laboratory and clinical observation data. You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges. LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component PhenX - health impact of inflammatory bowel disease protocol 190701. It is commonly used with the system or sample type ^Patient.

Reviewed by HealthAssure Clinical TeamUpdated 21 May 2026

What is this code?

LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component PhenX - health impact of inflammatory bowel disease protocol 190701. It is commonly used with the system or sample type ^Patient.

When is it used?

  • Used in lab systems, EHRs, and clinical data exchange.
  • May identify a test, observation, survey item, or clinical document request rather than a diagnosis.
  • Status: ACTIVE
  • Method: PhenX

What it does not mean

  • The code identifies the observation or test, not the actual result.

Key facts

PhenX - health impact of inflammatory bowel disease protocol 190701
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) obtains a clinical status in respondents who have been diagnosed with inflammatory bowel disease (IBD) (e.g., Crohn's disease and ulcerative colitis) using measures of health-related quality of life over the past 2 weeks. The protocol contains 10 questions that query the well-being of respondents in four realms relevant to IBD's impact on their livesemotional, social, bowel, and work. The questionnaire can be completed in less than 5 minutes. Because the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) should be administered to people who have already been diagnosed with Inflammatory Bowel Disease (IBD), the Gastrointestinal Working Group recommends including a filter question prior to administering the questionnaire. The filter question should ask if the subject has ever been diagnosed with inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. Administer the SIBDQ only if the subject answers "Yes" to this question. To further classify an IBD diagnosis, the Gastrointestinal Working Group (WG) recommends using the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium Phenotype Form in the Supplemental Information section for the Gastrointestinal WG.
Dis; Diseases; Dz; Health impact of inflamm bowel proto; IBD; Pan; Panel; PANEL.PHENX; Panl; Pnl; Point in time; Random

Where you may see this code

You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges.

Common synonyms

PhenX - health impact of inflammatory bowel disease protocol 190701Health impact of inflamm bowel protoPANEL.PHENX-Pt^PatientPhenX

Frequently asked questions

Code details

Code62965-9
SystemLOINC
Display namePhenX - health impact of inflammatory bowel disease protocol 190701
Short nameHealth impact of inflamm bowel proto
ComponentPhenX - health impact of inflammatory bowel disease protocol 190701
Property-
TimingPt
System (specimen)^Patient
Scale-
MethodPhenX
ClassPANEL.PHENX
StatusACTIVE

Flags

BillableNo
Valid clinical useNo

Source

SourceLOINC
Version2.82
Releasemain
First released2.36
Last changed2.81

Part names

PhenX - health impact of inflammatory bowel disease protocol 190701-Pt^PatientPhenXPoint in time (spot)

About this content

This page is prepared by HealthAssure's clinical team using official coding standards from LOINC. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.